Senior Executives from Disease Management Organizations and Media to Join InforMedix CEO on Institute on Aging (IOA) Board at the University of Pennsylvania.

ROCKVILLE, Md. -- InforMedix' CEO, the Chairman of the Board of Penn's Institute on Aging, to Forge Links Between the IOA and Chronic Disease Management Monitoring Services

InforMedix Holdings, Inc. (OTCBB:IFMX) announced today that its CEO, Bruce A. Kehr, M.D., Chairman of the External Advisory Board of the Institute on Aging (IOA) at the University of Pennsylvania, will be joined on the Board by two pioneers in providing disease management program services to senior citizens - David Chess, M.D., President and CEO of Enhanced Care Initiatives, and Sandeep Wadhwa, M.D., MBA, Vice President, McKesson Health Solutions, a division of McKesson Corp. In addition, Diane Linen Powell, a senior media and publishing entrepreneur, and venture capitalist was also named to the IOA Board.

Penn's IOA and faculty researchers are nationally renowned for their work in Alzheimer's disease, and other late-life chronic diseases. The IOA's External Advisory Board is comprised of leaders in the fields of aging, Alzheimer's disease, senior living and assisted living. The mission of the IOA is to improve the health of the elderly by increasing the quality and quantity of clinical and basic research as well as educational programs focusing on normal aging and age-related diseases.

Dr. Kehr stated, "I am excited to have David, Diane and Sandeep join our Board. David and Sandeep are nationally recognized pioneers and leaders in innovative home monitoring solutions for chronic disease patients, and will bring exciting opportunities to engage the IOA in this rapidly growing field. Diane is a highly accomplished media executive and businesswoman, has provided venture capital to grow early stage enterprises, and chairs the investment committee of another board where she oversees over $1 billion under management."

"We are delighted that Dr. Kehr nominated Drs. Chess and Wadhwa and Ms. Powell to our IOA Board," said John Q. Trojanowski, M.D., Ph.D. Director of the Institute on Aging at the University of Pennsylvania. "These innovative national experts in chronic care service delivery to the aged and entrepreneurship will assist us in developing additional sources of funding for our research and education programs regarding healthy aging, chronic disease management, and medication non-adherence in senior citizens."

Dr. David Chess, President and CEO of Enhanced Care Initiatives commented, "Most of my professional life has been devoted to designing and implementing care monitoring and management systems to improve medical care for the frail elderly patient. I am thrilled to be joining Penn's IOA to support their pioneering research into enhancing the lives of senior citizens with chronic diseases, and look forward to working closely with the IOA to achieve these objectives." Dr. Chess is a noted medical entrepreneur, having founded and built a 70 physician multi-specialty group practice with a significant clinical research arm, and has created innovative long term care, skilled nursing and home care health solutions.

Dr. Sandeep Wadhwa, Vice President, McKesson Health Solutions, is responsible for managing McKesson's disease management services, which offers disease management services to over 3,000,000 patients suffering from chronic diseases. Dr. Wadhwa completed an internal medicine residency, general internal medicine fellowship, and geriatrics fellowship from Penn Med and his MBA from Wharton. He noted, "I am delighted to return to the IOA to help advance its mission as a Board Member." Dr. Wadhwa has testified before Congress on multiple occasions, presented to news media important outcomes and trends regarding disease management for Medicaid and Medicare beneficiaries and conducted research centering on chronic disease prevention and health care economics. He is looking forward to assisting the IOA in broadening its relationship with policy makers in Washington and national news media.

Diane Linen Powell stated, "I am delighted to return to Penn to advance the IOA's mission, and to work with Dr. Kehr and other Board members on innovative new sources of funding for IOA activities." Ms Powell is the Chair of Des Plaines Publishing where she turned the fledgling company into one of the largest printers of ethnic newspapers and shoppers in the mid west. Her thirty-year career in the marketing and communications disciplines includes radio, cable television, network radio and television, Internet, broadcast property sales, trade associations and publishing, and investor relations. She has devoted extensive time to many charitable boards including Goodwill International, The Broadcasters' Foundation, The Shakespeare Theater, and the American Bible Society where she heads up the investment committee with nearly $1 billion under management. Powell was founding member of an angel venture capital group. She is a graduate of the University of Pennsylvania, cum laude, the University of Sussex in Falmer, England, and the Harvard Business School. Her husband, Ned, is the President and CEO of the USO.

As of June 2005, the members of IOA's External Advisory Board were: Richard P. Brown, Jr. Esquire, Counsel, Morgan Lewis & Bockius, LLP; Willo Carey, Executive Director, Wider Horizons, WHYY, Inc.; Christine Cassel, M.D., President and CEO, American Board of Internal Medicine; James E. Eden, Chairman and President, Eden & Associates; Robert Kasirer, Chairman and CEO, HealthCare Continuum; Barbara Kleger, President, KD Partners, LLC; C. Raymond Larkin, Jr., General Partner, 3X Nell, LLC; James L. McCabe, Ph.D., President, McCabe Capital Managers Ltd.; Daniel (Dan) Perry, Executive Director, Alliance on Aging Research; Vivian W. Piasecki; Orien Reid, Former Chair, National Board of Directors, Alzheimer's Disease Association; Thomas S. Rittenhouse, Managing Director, Ralston House; Gerald (Barry) B. Rorer, Senior Vice President, Rorer Group Inc.; Don Weissman, M.D.; and Linton A. Whitaker, M.D., Chief, Division of Plastic Surgery, PENN Medicine.

About InforMedix

InforMedix has developed the Med-eMonitor System as The Medication Adherence Solution for disease management and clinical drug trials markets. InforMedix has integrated a portable patient-interactive monitoring device, hardware, software and networked communications system to enable disease management programs, pharmaceutical and biotechnology companies, and medical researchers to efficiently monitor and manage patients' medication and care plan adherence, clinical response, and drug safety. Med-eMonitor is specifically designed to improve patient medication compliance and care plan adherence in disease management and clinical drug trials programs. In a recent program for diabetes patients, the Med-eMonitor System improved mean medication adherence rates to over 92% compared to a baseline medication adherence rate of 40%, and also reduced Hemoglobin A1c (HbA1c) levels by an average of 18.5% in a 3 month period (p value less than .002). The Med-eMonitor System leverages InforMedix's strong intellectual property consisting of 15 issued patents and 12 patents pending. InforMedix's patents have been cited as prior art by patent examiners in over 150 other issued patents. To find out more about InforMedix, Inc. (OTCBB:IFMX), visit our website at www.informedix.com.

This report contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. References made to the discussion of the risk factors are detailed in the Company's filings with the Securities and Exchange Commission, including our Annual Report on Form 10-KSB for the year ended December 31, 2004, our prospectus dated March 28, 2005 and our other filings with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise.